Boule Diagnostics AB 2020 AR2
The report highlights Boule Diagnostics AB's performance and sustainability initiatives during the 2020 fiscal year, which was heavily impacted by the COVID-19 pandemic. Despite challenging market conditions, the company continued to invest in its strategic next-generation hematology product platform, scheduled for launch in late 2022. Key achievements included the closure of the FDA warning letter from 2018 and the signing of a long-term 10-year supply agreement with a major OEM customer. On the sustainability front, Boule focused on product safety, reducing transport emissions, and maintaining high ethical standards, with 87% of critical suppliers signing its code of conduct.
Company: Boule Diagnostics AB
Sector: Health Care
Country: Sweden
Year: 2020
Type: AR2
Pages: 66
Boule Diagnostics AB
The report highlights Boule Diagnostics AB's performance and sustainability initiatives during the 2020 fiscal year, which was heavily impacted by the COVID-19 pandemic. Despite challenging market conditions, the company continued to invest in its strategic next-generation hematology product platform, scheduled for launch in late 2022. Key achievements included the closure of the FDA warning letter from 2018 and the signing of a long-term 10-year supply agreement with a major OEM customer. On the sustainability front, Boule focused on product safety, reducing transport emissions, and maintaining high ethical standards, with 87% of critical suppliers signing its code of conduct.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Jan 1, 2020 - Dec 31, 2020
Fiscal Year
2020
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees